Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||14/12/2021|
|Rapid review completed||10/01/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of regdanvimab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|